Aprotinin in coronary operation with cardiopulmonary bypass: Does "low-dose" aprotinin inhibit the inflammatory response?

Annals of Thoracic Surgery

Volumn 73, Issue 6, 2002, Pages 1897-1904

  Englberger, Lars ^a   Kipfer, Beat ^a   Berdat, Pascal A ^a   Nydegger, Urs E ^a   Carrel, Thierry P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; COMPLEMENT MEMBRANE ATTACK COMPLEX; D DIMER; FIBRINOPEPTIDE A; INTERLEUKIN 6; LACTOFERRIN; PLASMIN; PROTAMINE; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; CYTOKINE PRODUCTION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LEUKOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

APROTININ; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; FEMALE; FIBRINOLYSIS; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SERINE PROTEINASE INHIBITORS;

EID: 0036260092     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(02)03535-X     Document Type: Article

References (29)

1. The inflammatory response and extracorporeal circulation
2. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass
3. Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens
4. Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass
5. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting
6. Effects of minimal-dose aprotinin on coronary artery bypass grafting
7. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion
8. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans
9. Pump prime only aprotinin inhibits cardiopulmonary bapass-induced neutrophil CD11b-up-regulation
10. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations
11. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin
12. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release
13. Complement activation during major surgery: The effect of extracorporeal circuits and high-dose aprotinin
14. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children
15. Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass
16. Fibrin formation and degradation in patients with arteriosclerotic disease
17. A unified approach to rank tests for mixed models
18. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations
19. Impact of left ventricular dysfunction on cytokines, hemodynamics, and clinical outcome in bypass grafting
20. Activation of coagulation and fibrinolysis during cardiothoracic operations
21. Does the duration of cardiopulmonary bypass or aortic cross-clamp, in the absence of blood and/or blood product administration, influence the IL-6 response to cardiac surgery?
22. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization
23. Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms
24. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery
25. Neutrophil lactoferrin release during open heart surgery is unrelated to complement activation
26. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation
27. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement
28. Aprotinin: Safe and effective only with the full-dose regimen
29. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass